4th October 2022, Durham, UK
Magnitude Biosciences Limited, a company located on the North East Technology Park (NETPark) in Sedgefield, and one of the world’s leading commercial providers of services for determining the effects of compounds on ageing, longevity, neurodegeneration, and reproductive health, today announces the appointment of Fozia Saleem as Chief Executive Officer (CEO). David Weinkove, co-founder of Magnitude Biosciences who, as CEO and Chief Scientific Officer (CSO), has grown the business from an academic lab in Durham University in 2018 to a company with annual revenue of nearly £0.5m in 3 years, will continue as CSO.
Fozia joins from Broughton Life Sciences, a global life sciences consultancy, where she was Director of Product Development Services and a core member of the senior leadership team. She has a PhD in molecular physiology from the University of Edinburgh and started her career in industry at GlaxoSmithKline. Fozia subsequently worked for British American Tobacco and Nicoventures Holdings where she had a wide range of responsibilities, including product development, project delivery and revenue growth.
With the North East fast becoming a hot bed of talent and innovation, the notable rise in Life Sciences and Biomedical companies in the region are proud to call it their home. An industry that has been supported not only through available funding but by key advocates including Labour’s Shadow Science MP Chi Onwurah, who has been lending her voice as shadow science minister to the sector in Westminster and beyond. A voice that has most importantly helped in levelling up available investment and encouraging more of that funding back into the region.
A word from the Magnitude Team:
“I am thrilled to welcome Fozia to the Company to lead the next stage of its growth. There is significant interest and investment in companies developing products to help us live longer and healthier lives. Magnitude Biosciences offers research services to enable companies to rapidly identify the most promising compounds and is poised to benefit from the growth in this area. David is internationally renowned for his expertise in C. elegans research and his leadership of the scientific team and ability to design experiments to meet the often-challenging needs of companies will continue to drive growth of the business.”
– Sally Waterman, Chair, Magnitude Biosciences
“Really happy to welcome Fozia as our new CEO. She will further accelerate the amazing growth of our company, while I focus on our ground-breaking science to meet the research needs of our clients”
-David Weinkove, CSO, Magnitude Biosciences
“Looking forward to be joining the Magnitude Biosciences team, building on the foundations created by our 2 founders David Weinkove (CSO) and Chris Saunter (CTO), on generating high-quality, reproducible C. elegans data accelerating R&D across multiple industries.”
-Fozia Saleem, CEO, Magnitude Biosciences
To find out how Magnitude Biosciences can support your research contact us via info@magnitudebiosciences.com
Press Contact:
Jessica Evans jess@magnitudebiosciences.com
Sign up to our newsletter today, to get access to the latest company and industry news
